A Phase 2 interventional study of CIN-107 in Hypertension, sponsored by AstraZeneca. Completed at 36 sites in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-12-16.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing baxdrostat in Hypertension — 2 open to participants now, 4 under way, 3 of them phase 3. baxdrostat · Hypertension.
Among the 18 studies testing baxdrostat in Hypertension, this one is the 10th largest by enrollment, is one of 2 that started in 2022, is one of 5 in phase 2, and was the 3rd registered.
6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.
Browse Hypertension studies →2 of the 18 studies testing baxdrostat in Hypertension are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in China
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 39 more countries
Ages 18+
By country, each count listing its studies:
baxdrostat: first FDA approval 2026 (BAXFENDY). What it is approved for, and how studies give it, is on its page →
Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 175 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 197 across the 18 interventional studies. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 18 have an industry lead sponsor. The 2 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
71 studies in Hypertension by AstraZeneca: 4 open now, 6 under way, 3 of them phase 3. Of 65 finished, 15 (23%) have results posted.
Among the 71 studies in Hypertension by AstraZeneca, this one is the 22nd largest by enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2022, is one of 6 in phase 2, and was the 54th registered.
AstraZeneca’s Hypertension studies by the year they started, since 1998.
1 of the studies testing baxdrostat in Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07222917AstraZenecaA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. | 2026-12-10 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing baxdrostat in Hypertension, from their registry updates:
Among AstraZeneca’s 71 in Hypertension:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, multicenter, open-label extension (OLE) study to evaluate the long-term safety, tolerability, and effectiveness of CIN-107 for up to 52 weeks in patients with HTN who have completed Part 1 or Part 2 of Study CIN-107-124. The study will be conducted at clinical sites that have participated in the double-blind, Phase 2 Study CIN-107-124.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Agree to comply with the and reproduction restrictions of the study as follows:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment with 2 mg CIN-107 tablets, by mouth, once per day. Starting at Visit 1 and concluding at EOT (Visit 7).
Drug: CIN-107
2 mg of CIN-107, once a day for 52 weeks
Number of Participants With Any Treatment-emergent Adverse Events (TEAEs)
An AE was defined as any untoward medical occurrence in a clinical investigation participants administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and/or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational medicinal product, whether or not related to the investigational medicinal product. Any medical condition already present at enrollment should be recorded as medical history and not be reported as an AE unless the medical condition or signs or symptoms present at baseline changes in severity, frequency, or seriousness at any time during the study. In this case, it was be reported as an AE.
Time frame: 52 weeks
Number of Participants With Any Treatment-emergent Adverse Events of Special Interest (AESIs)
For this study, AESIs include the following: Events of hypotension that require clinical intervention; Abnormal potassium laboratory values that require clinical intervention; and Abnormal sodium laboratory values that require clinical intervention.
Time frame: 52 weeks
Number of Participants With Any Treatment-emergent Serious Adverse Events (TESAEs)
An AE was or adverse reaction is considered serious if, in the view of either the Investigator or Sponsor, it results in any of the following outcomes: Death, a life-threatening AE, a persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly/birth defect, or an important medical event.
Time frame: 52 weeks
Change From Baseline in Serum Potassium
Mean change from baseline at Week 52 in serum potassium (mmol/L).
Time frame: 52 weeks
Change From Baseline in Serum Sodium
Mean change from baseline at Week 52 in serum sodium (mmol/L).
Time frame: 52 weeks
Change From Baseline in Body Weight
Change from baseline at 52 weeks in body weight (kg)
Time frame: 52 weeks
Change From Baseline in Temperature
Change from baseline at 52 weeks in temperature (C)
Time frame: 52 weeks
Change From Baseline in Seated Heart Rate
Change from baseline at 52 weeks in seated heart rate (beats/min)
Time frame: 52 weeks
Change From Baseline in Mean Seated Systolic Blood Pressure
Mean change from baseline at Week 52 in seated systolic blood pressure (SBP)
Time frame: 52 weeks
Change From Baseline in Mean Seated Diastolic Blood Pressure
Mean change from baseline at 52 weeks in mean seated diastolic blood pressure (DBP)
Time frame: 52 weeks
Achieving Mean Seated Systolic Blood Pressure <130 mmHg
Number of participants achieved mean seated systolic blood pressure (SBP) \<130 mmHg at 52 week
Time frame: 52 weeks
Non-responders in Study CIN-107-124 Achieving a Seated SBP Response <130 mmHg
Number of non-responders (participants with seated SBP \>=130 mmHg) in Study CIN-107-124 achieving a seated SBP response \<130 mmHg with CIN-107 with/without a single background antihypertensive agent and/or rescue medication and irrespective of Study CIN-107-124 dose strength.
Time frame: 52 weeks
Responders in Study CIN-107-124 Achieving a Seated SBP Response <130 mmHg
Number of responders (participants with \<130 mmHg) in Study CIN-107-124 achieving a seated SBP response \<130 mmHg with CIN-107 with/without a single background antihypertensive agent and/or rescue medication and irrespective of Study CIN-107-124 dose strength.
Time frame: 52 weeks
| Milestone | 2mg CIN-107 |
|---|---|
| Started | 175 |
| Completed | 146 |
| Not completed | 29 |
| Withdrew: Lost to follow-up | 6 |
| Withdrew: Physician decision | 1 |
| Withdrew: Withdrawal by subject | 19 |
| Withdrew: Noncompliance, subject unable to complete last visit. | 3 |
An AE was defined as any untoward medical occurrence in a clinical investigation participants administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and/or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational medicinal product, whether or not related to the investigational medicinal product. Any medical condition already present at enrollment should be recorded as medical history and not be reported as an AE unless the medical condition or signs or symptoms present at baseline changes in severity, frequency, or seriousness at any time during the study. In this case, it was be reported as an AE.
| Participants | 2mg CIN-107 |
|---|---|
| Number of Participants With Any Treatment-emergent Adverse Events (TEAEs) | 73 |
For this study, AESIs include the following: Events of hypotension that require clinical intervention; Abnormal potassium laboratory values that require clinical intervention; and Abnormal sodium laboratory values that require clinical intervention.
| Participants | 2mg CIN-107 |
|---|---|
| Number of Participants With Any Treatment-emergent Adverse Events of Special Interest (AESIs) | 7 |
An AE was or adverse reaction is considered serious if, in the view of either the Investigator or Sponsor, it results in any of the following outcomes: Death, a life-threatening AE, a persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly/birth defect, or an important medical event.
| Participants | 2mg CIN-107 |
|---|---|
| Number of Participants With Any Treatment-emergent Serious Adverse Events (TESAEs) | 8 |
Mean change from baseline at Week 52 in serum potassium (mmol/L).
| mmol/L | 2mg CIN-107 |
|---|---|
| Change From Baseline in Serum Potassium | 0.08 ± 0.417 |
Mean change from baseline at Week 52 in serum sodium (mmol/L).
| mmol/L | 2mg CIN-107 |
|---|---|
| Change From Baseline in Serum Sodium | 0.6 ± 3.02 |
Mean change from baseline at Week 52 in seated systolic blood pressure (SBP)
| mmHg | 2mg CIN-107 |
|---|---|
| Change From Baseline in Mean Seated Systolic Blood Pressure | -5.1 ± 11.51 |
Mean change from baseline at 52 weeks in mean seated diastolic blood pressure (DBP)
| mmHg | 2mg CIN-107 |
|---|---|
| Change From Baseline in Mean Seated Diastolic Blood Pressure | -3.6 ± 8.65 |
Change from baseline at 52 weeks in body weight (kg)
| kg | 2mg CIN-107 |
|---|---|
| Change From Baseline in Body Weight | -0.30 ± 3.839 |
Change from baseline at 52 weeks in temperature (C)
| Celsius | 2mg CIN-107 |
|---|---|
| Change From Baseline in Temperature | -0.03 ± 0.473 |
Change from baseline at 52 weeks in seated heart rate (beats/min)
| beats/min | 2mg CIN-107 |
|---|---|
| Change From Baseline in Seated Heart Rate | 0.9 ± 9.49 |
Number of participants achieved mean seated systolic blood pressure (SBP) \<130 mmHg at 52 week
| Participants | 2mg CIN-107 |
|---|---|
| Achieving Mean Seated Systolic Blood Pressure <130 mmHg | 102 |
Number of non-responders (participants with seated SBP \>=130 mmHg) in Study CIN-107-124 achieving a seated SBP response \<130 mmHg with CIN-107 with/without a single background antihypertensive agent and/or rescue medication and irrespective of Study CIN-107-124 dose strength.
| Participants | 2mg CIN-107 |
|---|---|
| Non-responders in Study CIN-107-124 Achieving a Seated SBP Response <130 mmHg | 20 |
Number of responders (participants with \<130 mmHg) in Study CIN-107-124 achieving a seated SBP response \<130 mmHg with CIN-107 with/without a single background antihypertensive agent and/or rescue medication and irrespective of Study CIN-107-124 dose strength.
| Participants | 2mg CIN-107 |
|---|---|
| Responders in Study CIN-107-124 Achieving a Seated SBP Response <130 mmHg | 82 |
Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 2mg CIN-107 | 0/175 (0%) | 8/175 (4.6%) | 20/175 (11.4%) |
| Event | 2mg CIN-107 |
|---|---|
| Lacunar strokeNervous system disorders | 1/175 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/175 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/175 |
| Angina pectorisCardiac disorders | 1/175 |
| BradycardiaCardiac disorders | 1/175 |
| Myocardial infarctionCardiac disorders | 1/175 |
| DiverticulitisInfections and infestations | 1/175 |
| Femoral nerve injuryInjury, poisoning and procedural complications | 1/175 |
| Joint dislocationInjury, poisoning and procedural complications | 1/175 |
| HyperkalaemiaMetabolism and nutrition disorders | 1/175 |
| Event | 2mg CIN-107 |
|---|---|
| Urinary tract infectionInfections and infestations | 13/175 |
| HyperkalaemiaMetabolism and nutrition disorders | 9/175 |
| Age, Continuous(Years) | 2mg CIN-107 |
|---|---|
| Mean | 60.6 ± 10.4 |
| Age, Customized(Participants) | 2mg CIN-107 |
|---|---|
| > 75 years | 11 |
| <= 75 years | 164 |
| Sex: Female, Male(Participants) | 2mg CIN-107 |
|---|---|
| Female | 78 |
| Male | 97 |
| Ethnicity (NIH/OMB)(Participants) | 2mg CIN-107 |
|---|---|
| Hispanic or Latino | 99 |
| Not Hispanic or Latino | 76 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | 2mg CIN-107 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 4 |
| Black or African American | 42 |
| Native Hawaiian or other Pacific Islander | 0 |
| Other | 1 |
| White | 128 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
Ran from Apr 2022 to primary completion in Nov 2023, 19 months.
Results were first posted in Dec 2024, 1 year 1 month after primary completion.
Of 56 industry-sponsored phase 2 interventional studies under Hypertension, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 19 months is above that.
Counting every sponsor, half of 110 studies reached it within 25 months; a quarter within 11 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baxdrostat